Navigation Links
Synosia Starts Phase II Efficacy Trial For Rufinamide
Date:3/31/2008

The drug was originally discovered and developed by Novartis, which in 2004 granted certain licensing rights to Eisai, excluding anxiety and mood disorders. In January 2007, Eisai received marketing authorisation in the European Union for Inovelon(R) (rufinamide) as adjunctive anti-epileptic therapy in Lennox-Gastaut Syndrome (LGS), a severe form of epilepsy that develops in early childhood. The extensive clinical development program for rufinamide in epilepsy has generated over 2500 patient years of exposure to the drug.

About Synosia Therapeutics

Synosia Therapeutics develops and intends to commercialize innovative and clinically differentiated products for unmet medical needs in psychiatry and neurology. The privately-owned company has six clinical-stage compounds in its pipeline, acquired through key partnerships with Novartis, Roche and Syngenta. Synosia's pipeline includes two marketed drugs that will be tested in new indications, extending their reach into neurological and psychiatric diseases with high unmet medical need, including anxiety and Parkinson's Disease. Synosia's headquarters is in Basel, Switzerland. For more information visit http://www.synosia.com

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Synosia Therapeutics and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Synosia Therapeutics to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Synosia Therapeutics is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

References

'/>"/>
SOURCE Synosia Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Synosia Therapeutics Announces Appointment of Chief Business Officer
2. Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders
3. Synosia Therapeutics Appoints Chief Financial Officer to New Company Headquarters in Switzerland
4. Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration
5. Evotec Starts Phase II in Smoking Cessation with EVT 302
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
10. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
11. Phase III Trial Finds Pharmaxis Bronchitol Effective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... Rhinebeck, NY (PRWEB) May 17, 2013 ... by Topical BioMedics, Inc., has been listed among ... 2013 in an initiative conducted by "U.S. News" ... product has earned the “No. 1 Pharmacists ... with 17 other national OTC brands, and is ...
(Date:5/17/2013)... GA (PRWEB) May 17, 2013 Dr. ... Gynecology, and Women’s Health at the Albert Einstein College ... Oncology at the Montefiore Medical Center. He is ... Cancer Center and leads the Einstein Breast Cancer Working ... on translational breast cancer research. He also serves as ...
(Date:5/17/2013)... PA (PRWEB) May 17, 2013 Oven ... ramp/soak capabilities. The 5R6-900 temperature controller has many user-friendly ... be plugged into the wall as a self-contained ... supply. This distinctive detail makes the device unique, as ... The controller can also be used universally, which allows ...
(Date:5/17/2013)... transplant rejection occurs when the transplant recipient,s immune system ... it. It was previously thought that T cells, the ... by molecules known as chemokines in order to migrate ... Journal of Clinical Investigation , Fadi Lakkis and ... demonstrate that chemokine stimulation of T cells is not ...
Breaking Biology Technology:Pharmacists' Picks: Topical BioMedics' Topricin Listed on Top Recommended OTC Health Products 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 3New Temperature Control Products Announced by Oven Industries Inc. 2
... a thousand atoms, the electronic devices on semiconductor chips have ... Now for the first time, engineers have demonstrated a way ... , ,In a study published in the Aug. 1 issue ... professor of electrical and computer engineering, and Keith Thompson, David ...
... -- Brady Corp., a Milwaukee-based identification, safety, ... California visitor security software developer. , ,Brady did ... STOPware, Inc. , of San Jose. , ,STOPware, ... to identify and track visitors in a variety of ...
... The Illinois Biotechnology Industry Association (iBIO) recently held its ... Capitalists at the new Illinois Science & Technology Park in ... of reasons: , All of the VCs present were Midwest ... first event held at the new park, which many people ...
Cached Biology Technology:Engineers chart semiconductors on the scale of atoms 2Engineers chart semiconductors on the scale of atoms 3Engineers chart semiconductors on the scale of atoms 4Midwest venture capital funding declines in first half of 2005 2Midwest venture capital funding declines in first half of 2005 3
(Date:5/18/2013)... 2013) Research presented today at Digestive Disease Week ... findings about the impact of coffee on autoimmune disease ... coffee consumption recently has been associated with reduced risk ... few more cups of java each month also correlate ... Researchers at the Mayo Clinic, Rochester, MN, linked coffee ...
(Date:5/18/2013)... Orlando, FL (May 18, 2013) Research presented ... for managing digestive health through diet and lifestyle. ... often plagued by reduced muscle strength, fatigue and ... even when patients are in remission. A randomized, ... time that vitamin D supplementation corresponded to significant ...
(Date:5/18/2013)... 18, 2013) An increasing number of U.S. ... to resolve, according to research presented at Digestive ... targeting obesity, researchers at the Cleveland Clinic Children,s ... pattern of exhaled breath compared to their lean ... compound levels that can be correlated to potential ...
Breaking Biology News(10 mins):Coffee consumption associated with reduced risk of autoimmune liver disease 2Research examines new methods for managing digestive health 2Research examines new methods for managing digestive health 3New research identifies risks, interventions for children's GI health 2New research identifies risks, interventions for children's GI health 3
... it was the Pied Piper's tune. For the destructive sea ... pheromone, released by lamprey larvae living in streambeds. Following the ... Researchers have long wanted to identify the pheromone so it ... which laid waste to Great Lakes fisheries of lake trout ...
... Researchers in India and from The Earth Institute at ... remaining populations of Asian elephants in India is actually ... which appear in the current issue of the journal ... for the endangered elephants as well as other species ...
... treatment that spares disability from acute stroke may be ... ?a potential advance needed to benefit more stroke victims. ... that human umbilical cord blood cells administered to rats ... inflammatory response, reducing the size of the stroke and ...
Cached Biology News:Leading lampreys to slaughter: Pheromone for scourge of Great Lakes identified 2Leading lampreys to slaughter: Pheromone for scourge of Great Lakes identified 3Genetic analysis of Asian elephants in India reveals some surprises 2Cord blood cells may widen treatment window for stroke 2
... Grade C 19 H 9 Br 4 ... SPECIFICATIONS Form: Powder Clarity of Solution: Passes ... - Yellow pH 4.6 - Blue ... agarose and acrylamide gel electrophoresis. Used in ...
tracking dye in electrophoresis; free acid, C 19 H 10 BrO 5 S; MW: 669.96...
Denhardt's Solution is a mixture of blocking agents used in membrane-based hybridization protocols. The solution contains 1% Ficoll (type 400) 1% polyvinylpyrrolidone and 1% bovine serum albumin. Ste...
... ELF 97 Cytological Labeling Kit provides a ... detection of cellular targets, including cell-surface receptors ... Labeling Kit contains the patented ELF 97 ... yellow-green precipitate at the site of enzymatic ...
Biology Products: